Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.

ABSTRACT:

Background

Overactive bladder (OAB) is associated with considerable clinical and economic burden. Treatment of patients with OAB using anticholinergics is limited by tolerability issues and increased anticholinergic burden, which is associated with increased risk of dementia and falls/fractures. This analysis assessed the budget impact of introducing the β₃-adrenergic agonist vibegron for the treatment of patients with OAB from US commercial payor and Medicare perspectives.

Methods

A budget impact model (BIM) with a 5-year time horizon was developed using a top-down, prevalence-based approach and projected market shares for 1-million-member US commercial and Medicare plans. The BIM included vibegron, mirabegron, and anticholinergics, incorporating changes in clini

SUBMITTER: Chen JV 

PROVIDER: S-EPMC9522665 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature